In this study, we explored the antitumor effects of 9-ING-41, a maleimide-based ATP-competitive small molecule GSK-3β inhibitor, in bladder cancer cells when combined with an array of potentially active therapeutic agents12. This evidence concerns the gene GSK3B and urinary bladder carcinoma.